Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: outcome and minimal residual disease from the full population of the pivotal M13-982 trial Chyla, B., Stilgenbauer, S., Eichhorst, B., Schetelig, J., Munir, T., Hillmen, P., Seymour, J. F., Roberts, A. W., Coutre, S., Jurczak, W., Mulligan, S. P., Puvvada, S., Wendtner, C., Davids, M. S., Boettcher, S., Cerri, E., Zhou, L., Popovic, R., Poteracki, M., Arzt, J., Kim, S., Verdugo, M., Bhathena, A., Wierda, W., Hallek, M. TAYLOR & FRANCIS LTD. 2017: 234–35

View details for Web of Science ID 000423431100209